blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2714034

EP2714034 - COMPOSITIONS COMPRISING CEFEPIME AND TAZOBACTAM [Right-click to bookmark this link]
Former [2014/15]COMPOSITIONS COMPRISING ANTIBACTERIAL AGENT AND TAZOBACTAM
[2018/09]
StatusNo opposition filed within time limit
Status updated on  31.05.2019
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  22.06.2018
FormerGrant of patent is intended
Status updated on  08.02.2018
FormerExamination is in progress
Status updated on  26.01.2018
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Wockhardt Limited
D-4, MIDC Industrial Area Chikalthana
Aurangabad 431210 / IN
[2018/30]
Former [2014/15]For all designated states
Wockhardt Limited
D-4, MIDC Industrial Area Chikalthana
Aurangabad 431210 / IN
Inventor(s)01 / BHAGWAT, Sachin Subhash
Row House No.C-2
"Nilgiris"
Khivansara Park(E)
Behind Ramayana Cultural Hall, Ulkanagari
Aurangabad 431005 / IN
02 / JAFRI, Mohammad Alam
Plot No.180
Arif Colony
Ghati Road
Aurangabad 431001 / IN
03 / PATEL, Mahesh Vithalbhai
Plot No. 157
Opp. Saint Meera School
N-3, CIDCO
Aurangabad 431003 / IN
 [2014/15]
Representative(s)Nederlandsch Octrooibureau
P.O. Box 29720
2502 LS The Hague / NL
[2018/30]
Former [2014/15]May, Mark Andrew
MayReiprich Kirchgasse 2a
85354 Freising / DE
Application number, filing date11761404.001.08.2011
[2018/30]
WO2011IB53398
Priority number, dateIN2011MUM158728.05.2011         Original published format: IN 1587MU2011
[2017/16]
Former [2014/15]INMM1587201128.05.2011
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012164358
Date:06.12.2012
Language:EN
[2012/49]
Type: A1 Application with search report 
No.:EP2714034
Date:09.04.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 06.12.2012 takes the place of the publication of the European patent application.
[2014/15]
Type: B1 Patent specification 
No.:EP2714034
Date:25.07.2018
Language:EN
[2018/30]
Search report(s)International search report - published on:EP06.12.2012
ClassificationIPC:A61K31/407, A61K31/43, A61K31/431, A61K31/546, A61K31/04
[2014/15]
CPC:
A61K31/431 (EP,KR,US); A61K31/407 (EP,KR,US); A61K31/04 (KR);
A61K31/43 (EP,KR,US); A61K31/546 (EP,KR,US); A61P31/04 (EP);
A61P43/00 (EP); A61K2121/00 (KR); Y02A50/30 (EP,US) (-)
C-Set:
A61K31/407, A61K2300/00 (EP,US);
A61K31/431, A61K2300/00 (US,EP);
A61K31/43, A61K2300/00 (US,EP);
A61K31/546, A61K2300/00 (US,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/15]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ZUSAMMENSETZUNG ENTHALTEND CEFEPIME UND TAZOBACTAM[2018/09]
English:COMPOSITIONS COMPRISING CEFEPIME AND TAZOBACTAM[2018/09]
French:COMPOSITION COMPRENANT CEFEPIME ET TAZOBACTAM[2018/09]
Former [2014/15]ZUSAMMENSETZUNGEN MIT EINEM ANTIBAKTERIELLEN WIRKSTOFF UND TAZOBACTAM
Former [2014/15]COMPOSITIONS COMPRISING ANTIBACTERIAL AGENT AND TAZOBACTAM
Former [2014/15]COMPOSITIONS COMPRENANT UN AGENT ANTIBACTÉRIEN ET DU TAZOBACTAM
Entry into regional phase02.01.2014National basic fee paid 
02.01.2014Designation fee(s) paid 
02.01.2014Examination fee paid 
Examination procedure02.01.2014Examination requested  [2014/15]
04.08.2014Amendment by applicant (claims and/or description)
03.06.2016Despatch of a communication from the examining division (Time limit: M04)
26.09.2016Reply to a communication from the examining division
22.01.2018Cancellation of oral proceeding that was planned for 30.01.2018
30.01.2018Date of oral proceedings (cancelled)
09.02.2018Communication of intention to grant the patent
12.06.2018Fee for grant paid
12.06.2018Fee for publishing/printing paid
12.06.2018Receipt of the translation of the claim(s)
Divisional application(s)EP18184190.9  / EP3412289
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.06.2016
Opposition(s)26.04.2019No opposition filed within time limit [2019/27]
Fees paidRenewal fee
02.01.2014Renewal fee patent year 03
01.09.2014Renewal fee patent year 04
29.02.2016Renewal fee patent year 05
25.08.2016Renewal fee patent year 06
20.07.2017Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
31.08.201505   M06   Fee paid on   29.02.2016
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL25.07.2018
CY25.07.2018
EE25.07.2018
FI25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
MK25.07.2018
RS25.07.2018
SI25.07.2018
SK25.07.2018
SM25.07.2018
LU01.08.2018
MT01.08.2018
BG25.10.2018
IS25.11.2018
[2020/31]
Former [2020/08]AL25.07.2018
EE25.07.2018
FI25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
RS25.07.2018
SI25.07.2018
SK25.07.2018
SM25.07.2018
LU01.08.2018
MT01.08.2018
BG25.10.2018
IS25.11.2018
Former [2019/37]AL25.07.2018
EE25.07.2018
FI25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
RS25.07.2018
SI25.07.2018
SK25.07.2018
SM25.07.2018
LU01.08.2018
BG25.10.2018
IS25.11.2018
Former [2019/27]AL25.07.2018
EE25.07.2018
FI25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
RS25.07.2018
SK25.07.2018
SM25.07.2018
LU01.08.2018
BG25.10.2018
IS25.11.2018
Former [2019/24]AL25.07.2018
EE25.07.2018
FI25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
RS25.07.2018
SK25.07.2018
LU01.08.2018
BG25.10.2018
IS25.11.2018
Former [2019/21]AL25.07.2018
FI25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
RS25.07.2018
LU01.08.2018
BG25.10.2018
IS25.11.2018
Former [2019/12]AL25.07.2018
FI25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
RS25.07.2018
BG25.10.2018
IS25.11.2018
Former [2019/11]FI25.07.2018
HR25.07.2018
LT25.07.2018
RS25.07.2018
BG25.10.2018
IS25.11.2018
Former [2019/08]FI25.07.2018
LT25.07.2018
IS25.11.2018
Former [2019/07]LT25.07.2018
Cited inInternational search[XAI] CN1565455  (CHENGDU BORUI MEDICINE TECHNOL et al.) [X] 1-8,12,21-24,27 * abstract * * the whole document *[A] 13-20,26 [I] 9-11,25,28
 [XAI] CN1565456  (ZHANG ZHEFENG et al.) [X] 1-8,12,21-24,27 * abstract * * the whole document *[A] 13-20,26 [I] 9-11,25,28
 [XAI] WO2007086011  (SRINIVAS JEGANNATHAN et al.) [X] 1-7,12,21-24 * the whole document * * in particular * * page 1, paragraph 1 * * page 4, paragraph 2 * * claims 1-4 *[A] 13-20,26 [I] 8-11,25,27,28
 [XAI] WO2007086014  (SRINIVAS JEGANNATHAN et al.) [X] 1-4,13-15,20-24 * the whole document * * in particular * * page 1, paragraph 1 * * page 3, paragraph 5 * * page 4, paragraph 2 * * claims 1-4 *[A] 5-12,25 [I] 16-19,26-28
 [IA] US2010197650  (BIEK DONALD et al.) [I] 1-4,21-24 * paragraphs [0115] , [ 117] , [ 118] * * tables 12-14 *[A] 5-20,25-28
 [XAI]   A. ENDIMIANI ET AL: "Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 63, no. 3, 15 January 2009 (2009-01-15), pages 427 - 437, XP055017325, ISSN: 0305-7453, DOI: 10.1093/jac/dkn547 [X] 1-3,5-7,21,22 * the whole document * * in particular * * abstract * * Antimicrobial susceptibility testing; page 429, column 1 * * Antimicrobial susceptibility tests; page 429, column 2 * * table 2 * * In vitro activity; page 435, column 1 *[A] 13-20,26 [I] 4,8-12,23-25,27,28

DOI:   http://dx.doi.org/10.1093/jac/dkn547
 [XAI]   JONES R N ET AL: "Antimicrobial spectrum of cefpirome combined with tazobactam against the Bacteroides fragilis group", DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASES, ELSEVIER SCIENCE PUBLISHING CO., AMSTERDAM, NL, vol. 13, no. 5, 1 September 1990 (1990-09-01), pages 371 - 373, XP023790076, ISSN: 0732-8893, [retrieved on 19900901], DOI: 10.1016/0732-8893(90)90004-F [X] 1-3,13-15,21,22 * the whole document *[A] 5-12,25 [I] 4,16-20,23,24,26-28

DOI:   http://dx.doi.org/10.1016/0732-8893(90)90004-F
ExaminationUS2010029604
   MACGOWAN ALASDAIR; ROGERS CHRIS; BOWKER KAREN: "In vitro models, in vivo models, and pharmacokinetics: What can we learn from in vitro models?", CLINICAL INFECTIOUS DISEASES, vol. 33, no. Suppl. 3, 15 September 2001 (2001-09-15), pages S214 - S220
   VANSCOY BRIAN D ET AL.: "Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 61, no. 12, 1 December 2017 (2017-12-01) [P]
   21 December 2017 (2017-12-21), Retrieved from the Internet [retrieved on 20171221] [P]
by applicant  MAYER ET AL.: "Investigation of the aminoglycosides, fluoroquinolones and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp.", J. ANTIMICROB. CHEMOTHER., vol. 43, 1999, pages 651 - 657 [X] 1-3,5-7,21,22 * the whole document * * in particular * * abstract * * Antimicrobial susceptibility testing; page 429, column 1 * * Antimicrobial susceptibility tests; page 429, column 2 * * table 2 * * In vitro activity; page 435, column 1 *[A] 13-20,26 [I] 4,8-12,23-25,27,28
   GRADELSKI ET AL.: "Synergistic activities of gatifloxacin in combination with other antibacterial agents against clinical isolates of Pseudomonas aeruginosa and related species", ANTIMICROB. AGENTS CHEMOTHER., vol. 45, 2001, pages 3220 - 3222 [A] 13-20,26 [I] 9-11,25,28
   FISH ET AL.: "Synergistic activity of cephalosporins plus fluroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs", J. ANTIMICROB. CHEMOTHER., vol. 50, 2002, pages 1045 - 1049 [A] 13-20,26 [I] 9-11,25,28
   DAVIS ET AL.: "In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms", J. ANTIMICROB. CHEMOTHER., vol. 51, 2003, pages 1203 - 1211 [X] 1-3,13-15,21,22 * the whole document * [A] 5-12,25 [I] 4,16-20,23,24,26-28
   N. SIVAGURUNATHAN ET AL.: "Synergy of gatifloxacin with cefoperazone and cefoperazone-sulbactam against resistant strains of Pseudomonas aeruginosa", J. MEDICAL MICROB., vol. 57, 2008, pages 1514 - 1517 [A] 13-20,26 [I] 8-11,25,27,28
   AL-HASAN: "p-Lactam and Fluroquinolonecombination antibiotic therapy for bateremia caused by Gram-negative bacilli", ANTIMICROB. AGENTS CHEMOTHER., vol. 53, no. 4, 2009, pages 1386 - 1394 [A] 5-12,25 [I] 16-19,26-28
   OILMAN ET AL.: "Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Ed.,", 1990, PERGAMON PRESS [A] 5-20,25-28
   CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI, vol. 30, no. 1, 2010, pages M 100 - S20
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.